ParabilisMed

Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to developing a new class of medicines called Helicon peptides to target "undruggable" intracellular proteins. The company's proprietary Helicon platform combines AI, physics-based algorithms, and laboratory innovation to create stabilized, cell-penetrant alpha-helical peptides. Its lead candidate, zolucatetide (formerly FOG-001), is a first-in-class direct inhibitor of the β-catenin:TCF interaction, currently in Phase 1/2 trials for various solid tumors including colorectal cancer and desmoid tumors. Parabilis is also advancing a pipeline of protein degraders and radioligand therapies targeting historically intractable drivers of cancer like ERG and the androgen receptor. The company rebranded from FogPharma in 2024 to reflect its mission of making previously impossible treatments obtainable for patients globally.